fashion -WSS

fashion

author：focus 2025-10-01 22:59:26 - browse：9

Two people run on the sugar-phosphate backbone of DNA while holding base pairs — in the lab coverage from STAT — Adobe

LONDON — Widespread genetic testing as well as the development of cutting-edge, customized genetic therapies have opened the door to treating many more inherited conditions than previously possible. A few recent cases, in which bespoke medicines were created for children with exceedingly rare mutations, have raised hopes for furthering the approach.

Now, researchers and government agencies in the U.K. are trying to figure out the nitty-gritty to replicate those early one-off successes for as many patients as possible — what sort of preclinical testing a tailor-made treatment needs to go through before being used, what regulatory thresholds each treatment needs to clear, and how to pay for these therapies.

“A lot of the barriers are no longer scientific — we can make these drugs,” said Matthew Wood, a professor of pediatrics at the University of Oxford. “It’s more about, can we make them at a cost that is reasonable enough? And can we get the regulators to reduce the barriers to doing this so that when a patient shows up, you can actually make a drug quickly enough to benefit that patient, rather than it costing huge amounts of money and taking two or three years to do it?”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： FDA approval of Sarepta Duchenne genetic therapy gives me hope

explore

WSS

Lessons Learned: This is why you network to find that industry job you want

Wegovy cuts risk of cardiovascular events by 20%, study finds

CDC launches VaccineFinder tool to locate Covid

Judge rejects Trump's counterclaim against E. Jean Carroll

Germany receives 178 compensation applications from gay servicepeople over discrimination

Supreme Court strikes down use of affirmative action

explore

fashion

focus

BioMarin wins approval for gene therapy to treat hemophilia A

NYC struggling to keep up with demand of supporting asylum seekers, Mayor Adams says

Malaria cases in Florida and Texas: Here’s what you need to know

Cancer drug shortages should be causing more outrage

At least 13 dead in Texas as scorching temps continue

Wegovy cuts risk of cardiovascular events by 20%, study finds

BioMarin wins approval for gene therapy to treat hemophilia A

23andMe had bad news about my health. I wish a person had delivered it

Anesthesiologist group: stop taking Ozempic before surgery

An Ebola outbreak presents a new mystery involving children

entertainment

Choosing scientific sides in the fight against Alzheimer's

The cancer drug shortage isn’t new — and neither are the solutions

Supreme Court strikes down use of affirmative action

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Medicare proposal to cover medical devices draws a mixed reaction

‘The Bear’ and hospitality in hospitals

focus

Wikipedia

explore

focus